ATE311205T1 - Verwendung von viralen vektoren und geladenen molekülen für die gentherapie - Google Patents

Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Info

Publication number
ATE311205T1
ATE311205T1 AT00941379T AT00941379T ATE311205T1 AT E311205 T1 ATE311205 T1 AT E311205T1 AT 00941379 T AT00941379 T AT 00941379T AT 00941379 T AT00941379 T AT 00941379T AT E311205 T1 ATE311205 T1 AT E311205T1
Authority
AT
Austria
Prior art keywords
gene therapy
viral vectors
charged molecules
molecules
charged
Prior art date
Application number
AT00941379T
Other languages
English (en)
Inventor
Francis Tufaro
Sonia Yeung
Brian Horsburgh
Original Assignee
Medigene Inc
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Inc, Univ British Columbia filed Critical Medigene Inc
Application granted granted Critical
Publication of ATE311205T1 publication Critical patent/ATE311205T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00941379T 1999-06-11 2000-06-12 Verwendung von viralen vektoren und geladenen molekülen für die gentherapie ATE311205T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13887599P 1999-06-11 1999-06-11
PCT/US2000/016167 WO2000076553A1 (en) 1999-06-11 2000-06-12 Use of viral vectors and charged molecules for gene therapy

Publications (1)

Publication Number Publication Date
ATE311205T1 true ATE311205T1 (de) 2005-12-15

Family

ID=22484057

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941379T ATE311205T1 (de) 1999-06-11 2000-06-12 Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Country Status (9)

Country Link
US (1) US20040166092A1 (de)
EP (1) EP1185306B1 (de)
JP (1) JP2003501111A (de)
AT (1) ATE311205T1 (de)
AU (1) AU777120B2 (de)
CA (1) CA2376956A1 (de)
DE (1) DE60024442T2 (de)
ES (1) ES2252017T3 (de)
WO (1) WO2000076553A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004035779A1 (ja) * 2002-08-27 2006-02-16 アンジェスＭｇ株式会社 ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646178A1 (de) * 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US20020010144A1 (en) * 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5827707A (en) * 1995-06-07 1998-10-27 Neocrin Company Method for manufacturing minimal volume capsules containing biological materials
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
EP0857217B1 (de) * 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Neue expressionsvektoren und verfahren zu deren verwendung
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6569426B2 (en) * 1997-04-03 2003-05-27 Genzyme Corporation Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
JP2002525065A (ja) * 1998-09-11 2002-08-13 ジェンベク、インコーポレイティッド 選択的にターゲッティングされるアデノウイルス
US6599909B1 (en) * 1998-09-29 2003-07-29 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20050063950A1 (en) * 1998-11-19 2005-03-24 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
AU777120B2 (en) 2004-09-30
ES2252017T3 (es) 2006-05-16
US20040166092A1 (en) 2004-08-26
EP1185306A1 (de) 2002-03-13
DE60024442D1 (de) 2006-01-05
EP1185306A4 (de) 2002-07-10
JP2003501111A (ja) 2003-01-14
AU5608900A (en) 2001-01-02
WO2000076553A1 (en) 2000-12-21
CA2376956A1 (en) 2000-12-21
DE60024442T2 (de) 2006-08-03
EP1185306B1 (de) 2005-11-30

Similar Documents

Publication Publication Date Title
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE366806T1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
DE69533564D1 (de) Effektor-Proteine für Rapamycin
DE60032486D1 (de) Prion protein peptide und deren verwendung
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
ATE404667T1 (de) Chromatin-regulatorgene
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
MX9602557A (es) Proteinas de higado de mamifero y su uso en oncologia.
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
DK0906443T3 (da) Generering af replikerende molekyler in vivo
DE69739346D1 (de) Gereinigtes sr-p70 protein
ATE311205T1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
DK0942992T3 (da) O-fucosyltransferase
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
ATE528392T1 (de) Neues protein und dessen dns

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185306

Country of ref document: EP

REN Ceased due to non-payment of the annual fee